ACP
ALGS icon

Altitude Crest Partners’s Aligos Therapeutics ALGS Stock Holding History

Altitude Crest Partners’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-113,787
Closed -$2.79M – 2
2024
Q1 		$2.79M Hold
113,787
– – 1.19% 23
2023
Q4 		$1.89M Buy
+113,787
New +$1.96M 1.26% 10

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Altitude Crest Partners's ALGS Position: Q2 2024 in Review

Altitude Crest Partners sold out of Aligos Therapeutics (ALGS) in Q2 2024, closing a stake of 113,787 shares — an estimated $2.79M sold.

Altitude Crest Partners first reported a position in ALGS in Q4 2023 and held it in 2 quarters. The position peaked at $2.79M in Q1 2024. 48 funds tracked by Wall St. Rank hold ALGS as of Q2 2024.

  • Altitude Crest Partners reported no remaining Aligos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 113,787 Aligos Therapeutics shares in Q2 2024, an estimated $2.79M.
  • Altitude Crest Partners first reported a position in Aligos Therapeutics in Q4 2023 and held it in 2 quarters.
  • Altitude Crest Partners's Aligos Therapeutics position peaked at $2.79M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.